Key result
This review discusses the molecular pathophysiology of catecholaminergic polymorphic ventricular tachycardia and potential therapeutic strategies for controlling calcium-handling abnormalities.
This review summarizes the molecular pathophysiology of catecholaminergic polymorphic ventricular tachycardia (CPVT) and discusses potential innovative strategies for controlling calcium-handling abnormalities.
May guide future CPVT therapies targeting calcium handling; leaves open need for clinical validation before practice change.
Development of cardiac arrhythmias in several degenerative cardiac disorders such as heart failure is precipitated by abnormalities in intracellular calcium regulation. Recently, the identification of mutations in proteins responsible for the control of intracellular calcium has been associated with an inherited arrhythmogenic syndrome called catecholaminergic polymorphic ventricular tachycardia (CPVT). Here, we review the current knowledge about the molecular pathophysiology of CPVT and we discuss some potentially innovative strategies for controlling calcium-handling abnormalities in CPVT that may provide novel therapeutic options for affected patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2007) conducted a review in Catecholaminergic polymorphic ventricular tachycardia (CPVT). This review discusses the molecular pathophysiology of catecholaminergic polymorphic ventricular tachycardia and potential therapeutic strategies for controlling calcium-handling abnormalities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: